Category: Clinical Trial
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Study Name Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation ClinicalTrials.gov…
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Study Name Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations ClinicalTrials.gov Identifier (if applicable) NCT04579380 Clinical…
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Study Name This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in…
ICP-CL-00303
Study Name ICP-CL-00303 ClinicalTrials.gov Identifier (if applicable) NCT04565275 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted…
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)
Study Name Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS…
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Study Name Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors ClinicalTrials.gov Identifier (if applicable) NCT04056910 Clinical Trial Category (check all…
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)
Study Name CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the…
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Study Name CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT04660929 Clinical Trial Category (check…
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Study Name Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating…
A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma (HELIX-ICC)
Study Name A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given…
TAS-120-301(FOENIX-CCA3)
Study Name TAS-120-301(FOENIX-CCA3) ClinicalTrials.gov Identifier (if applicable) NCT04093362 Clinical Trial Category (check all that apply) First Line Therapy Study Center…
Gemcitabine and Cisplatin With or Without CPI-613 (Devimistat)as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Study Name Gemcitabine and Cisplatin With or Without CPI-613 (Devimistat)as First Line Therapy for Patients With Advanced Unresectable Biliary Tract…